19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.



powered by centersite dot net
Child & Adolescent Development: Overview
Basic InformationMore InformationLatest News
U.S. Teachers Often Faced Harassment, Violence During Pandemic: PollOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaSuicide Rate Is Spiking Upwards in Preadolescent ChildrenAHA News: Bystander CPR on Kids Differs by Race and EthnicityNew Malaria Treatment Gets First Approval for Use in ChildrenMental Health of America's Children Only Getting WorseTalking to Your Kids About the War in UkraineOdds for Mental Illness Rise in Kids After ConcussionPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Pfizer Vaccine Much Less Potent in Kids Aged 5-11COVID Has Robbed 5.2 Million Children Worldwide of Parent, CaregiverNew Drug May Help Curb COVID-Linked Inflammatory Disorder in KidsPoll Finds Most Parents Would Use CBD to Treat a Child — Is That Wise?Does Your Child Have Asthma? Look for the SignsResearch May Help Focus Treatment for Kids With Cystic FibrosisSleepless Children Often Become Sleepless Adults: StudyA Healthy Mouth Could Be a Lifesaver for Kids With Heart ConditionsSeasonal Flu Shots Give Kids Broader Protection Against New StrainsU.S. Kids Still Dying From Toppling TVs, FurnitureKids With COVID-Linked MIS-C Have Long-Term SymptomsAHA News: Amid a National Mental Health Crisis For Kids, Here's How Parents Can HelpParents: What You Need to Know About Kids & COVID-19Getting Active Soon After Concussion May Aid Kids' RecoveryPfizer Asks FDA to Approve Its Vaccine for Youngest KidsThe 'Oreo Test' and Other Ways to Help Kids' Oral HealthPfizer Will Ask FDA to Approve Its COVID Vaccine for Kids Under 5Getting Your School-Age Child Into a Healthy Sleep RoutineGenes Could Help Drive Febrile Convulsions in KidsMore Than 1 Million U.S. Kids Diagnosed With COVID in Single WeekPandemic Especially Tough on Kids With ADHDBrain Implant for Adults With Epilepsy Can Help Kids, TooCOVID Can Affect Brains of Hospitalized KidsMany Kids Aren't Wearing Helmets While Sledding, Poll FindsMany Marijuana Vendors Aim Advertising at Kids: StudyHeart Function Rebounds for Kids With COVID-Linked MIS-CWhich Kids Are Most Vulnerable to Severe COVID-19?At-Home COVID Tests Accurate for Ki​ds: StudyCDC Study Shows Power of Flu Vaccine for KidsCOVID Hospitalizations Rising in Kids Too Young for VaccineNearly 600,000 U.S. Kids Had COVID Last WeekWhite House to Give Schools 10 Million Free COVID Tests Every MonthKids' Behavior Worsened With Remote Learning: StudyLater School Start Times Boost Parents' Health, TooUrban Air Pollution Drives Millions of Cases of Asthma in KidsCDC Backs Boosters for High-Risk Kids Aged 5-11, Shorter Time Between ShotsA Better Way to Correct Severe Scoliosis in Kids?Getting Your Child Their Vaccine?  Some Tips on Easing Needle FearsU.S. Hospitals Seeing Record Numbers of Young COVID PatientsSevere Illness in Children Brings Hardship for FamiliesReal-World Data Confirms Pfizer Vaccine Safe for Kids Ages 5-11
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses

Pfizer Will Ask FDA to Approve Its COVID Vaccine for Kids Under 5

HealthDay News
by Robin Foster
Updated: Feb 1st 2022

new article illustration

TUESDAY, Feb. 1, 2022 (HealthDay News) -- Pfizer Inc. plans to ask the U.S. Food and Drug Administration as soon as Tuesday to authorize its COVID vaccine for emergency use in children aged 6 months to 4 years old.

If approved, the two-shot regimen would become the first approved for use in children this young; older children are already eligible for the vaccine. In December, Pfizer suffered a setback when it announced that two doses of the vaccine, which are one-tenth the amount of an adult dose, did not produce a sufficient immune response in children aged 2 to 4. The company has already started testing a third dose in this age group.

“At this time, we have not filed a submission and we’re continuing to collect and analyze data from both two and three doses in our younger age cohort,” Pfizer spokeswoman Jerica Pitts told the Washington Post on Monday. “As part of our ongoing commitment, we will share new updates as they become available.”

But federal regulators have been eager to review Pfizer's data in hopes of authorizing shots for young children as early as the end of February, multiple people familiar with the discussions told the Post. If Pfizer waits for data on three doses in these youngest Americans, the data would not be submitted until late March and the vaccine might not be authorized for that age group until weeks later, the newspaper said.

“We know that two doses isn’t enough, and we get that,” one of the people familiar with the situation told the Post. “The idea is, let’s go ahead and start the review of two doses. If the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don’t do anything until the third-dose data comes in.”

Last Friday, Pfizer briefed federal health officials on updated trial data on the shots, an administration official who spoke on the condition of anonymity, told the newspaper.

Those attending the briefing included Dr. Anthony Fauci; David Kessler, chief science officer for the government's COVID-19 response; a representative from the U.S. Centers for Disease Control and Prevention; and other officials from the U.S. Department of Health and Human Services, the Post reported.

The session included a “robust conversation” that three doses were likely to be much more powerful than just two shots, the administration official said. “But to get to three, you have to get two shots first. … There’s interest in seeing this move forward,” the official told the Post. Expert advisory panels to both the FDA and the CDC are expected to meet on the two-dose application sometime in February.

As the Omicron variant has consumed the country, there has been a sharp increase in pediatric cases of the virus, according to the American Academy of Pediatrics (AAP), which gathers state-level data. Even though most young children tend to do well combating the virus, some can get very ill. Federal officials and experts are anxious to begin a vaccination program for the youngest children because the Pfizer studies showed there were no safety concerns with two doses.

“We understand the urgent need for a safe and effective vaccine for that age group,” AAP CEO Mark Del Monte said in a statement, the Post reported. “We are eager to see the data and will continue to follow the science.”

More information

Visit the U.S. Food and Drug Administration for more on COVID vaccines.

SOURCE: Washington Post